SHR-A1904 + capecitabine + oxaliplatin + adebrelimab

This is a combination regimen of four anticancer agents investigated for first-line treatment of advanced CLDN18.2-positive solid tumors, especially gastric and gastroesophageal junction cancers. - **SHR-A1904** is an antibody-drug conjugate targeting CLDN18.2, a protein selectively expressed in certain gastric and GEJ tumors. It consists of a monoclonal antibody directed at CLDN18.2, linked via a cleavable peptide-based linker to a DNA topoisomerase I inhibitor payload, enabling targeted cytotoxicity to tumor cells[5][7]. - **Capecitabine** is an oral prodrug of fluorouracil (5-FU), an antimetabolite that inhibits both DNA and RNA synthesis[2][10]. - **Oxaliplatin** is a platinum-based chemotherapeutic that induces DNA crosslinks and apoptosis. - **Adebrelimab** is a monoclonal antibody targeting PD-L1, functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. This four-drug combination is studied in clinical trials (NCT06350006) in phase 1 and phase 3 settings for advanced, CLDN18.2-positive solid tumors[1].

Other names

CAPOX